Over the counter home test for COVID-19 gets US approval
Ellume home test kit will be priced around $30 and be available for purchase at pharmacies and online.
The first home test for COVID-19 that doesn’t require a prescription will soon be on U.S. store shelves.
U.S. regulators on Dec. 15 authorized the rapid coronavirus test, which can be done entirely at home. The announcement by the FDA represents another important — though incremental — step in efforts to expand testing options.
The agency’s action on Dec. 15 allows sales in places like drugstores “where a patient can buy it, swab their nose, run the test and find out their results in as little as 20 minutes,” said FDA Commissioner Stephen Hahn, in a statement.
Initial supplies of the over-the-counter test will be limited. Australian manufacturer Ellume said it expects to produce 3 million tests next month before ramping up production over the first half of 2021.
A company spokesperson said the test will be priced around $30 and be available at pharmacies and for purchase online.
The kit includes a nasal swab, a chemical solution and a testing strip. The test connects digitally to a smart phone app that displays the results and then helps interpret the results. Users can also connect with a health professional via the app.
For months, health experts have stressed the need for fast, widespread home testing so that people can screen themselves and avoid contact with others if they have an infection. But the vast majority of tests still require a nasal swab performed by a health processional that must be processed at high-tech laboratories. That typically means waiting days for the results. About 25 tests allow people to collect their own sample at home — a nasal swab or saliva — but then that’s shipped to a lab.
Ellume’s test looks for viral proteins shed by COVID-19, which is different from the gold standard tests that look for the genetic material of the virus.
Currently the U.S. is testing nearly 2 million people daily. Most health experts agree the country needs to be testing many times more and researchers at Harvard have pushed for cheap, paper home tests.